Logo
Login

Company Executives

$ Management Team

Mr. Andrew Gengos

Chief Financial Officer

Treasurer

Age 60
Compensation -
Sex Male

Ms. Sun Jung

Chief Business Officer

Age 47
Compensation $2.196M USD
Sex Female

Mr. David Fellows

Independent Chairman of the Board

Age 68
Compensation $234.8K USD
Sex Male

Ms. Amy Burroughs

Chief Executive Officer

Director

Age 55
Compensation $8.241M USD
Sex Female

Dr. Emil Kuriakose

Chief Medical Officer

Age 45
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 29, 2025
Directors
8
serving now
Independent
0 of 1
stated in the proxy; 7 not stated
Average tenure
3.1 years
from year joined
CEO also chairs the board
No
David Fellows
Director Age On board Independent Committees Other public boards 2024 pay Source
Robert Azelby
57 2025
0 years
 Not stated
Compensation Committee
ADC Therapeutics SA, Autolus Therapeutics plc, Cardinal Health, Inc. Not stated
Hongbo Lu
54 2020
5 years
 Not stated
Nominating and Corporate Governance Committee
RiboX Therapeutics Ltd., Visirna Therapeutics (Suzhou) Co., Ltd., Zenas BioPharma, Inc. Not stated
Heather Turner
52 2024
1 year
 Not stated
Audit Committee
Avalyn Pharma, Inc. $249,800
David Fellows
Board chair
 68 2020
5 years
 Not stated
Nominating and Corporate Governance Committee · Chair
Beacon Therapeutics Holdings Limited, Jaguar Gene Therapy, LLC $234,829
Jill Quigley
50 2020
5 years
 Not stated
Audit Committee · Chair
Chemomab Therapeutics Ltd. $300,457
Radhika Tripuraneni
45 2022
3 years
 Not stated
Research and Development Committee · Chair
None stated $205,922
Jeffrey Kindler
69 2020
5 years
 Not stated
Compensation Committee · Chair
Perrigo Company plc, Precigen, Inc., Lupin $198,268
Amy Burroughs
CEO
 55 2024
1 year
 Not independent None stated Tenaya Therapeutics, Inc. Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 29, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans